SQUAWK/NEWS
Account
Theme
Account
Menu
Live News GEOPOLITICS ARTICLE H impact

White House pulls Overton’s FDA nomination

Sen. Roger Marshall, R-Kansas, is being weighed as a potential replacement. Capitol Hill is grappling with the prospect of the Food and Drug Administration operating without a Senate-confirmed leader indefinitely, after the White House pulled the nomination of Heidi Overton to lead the agency Tuesday night. It’d been unclear whether the embattled White House official could get the necessary votes to be confirmed by the Senate’s health committee from lawmakers skeptical of her positions on vaccines, the abortion pill, and flavored vapes. But Chair Bill Cassidy, R-La., asserted after the nomination was dropped that he believed the White House “abandoned a viable confirmation path.” “Pro-life Senators sought final assurances from the Administration regarding the Administration’s commitment to life issues,” Cassidy said. “The Administration withdrew Dr. Overton rather than make such commitments.” Sen. Roger Marshall, R-Kansas, is being weighed as a potential replacement, but there are questions swirling about whether anyone could be confirmed on a compressed timeline before Democrats take power. Chris Meekins, a Raymond James healthcare analyst who worked at HHS during Trump’s first te

Sen. Roger Marshall, R-Kansas, is being weighed as a potential replacement. Capitol Hill is grappling with the prospect of the Food and Drug Administration operating without a Senate-confirmed leader indefinitely, after the White House pulled the nomination of Heidi Overton to lead the agency Tuesday night. It’d been unclear whether the embattled White House official could get the necessary votes to be confirmed by the Senate’s health committee from lawmakers skeptical of her positions on vaccines, the abortion pill, and flavored vapes.

But Chair Bill Cassidy, R-La., asserted after the nomination was dropped that he believed the White House “abandoned a viable confirmation path.” “Pro-life Senators sought final assurances from the Administration regarding the Administration’s commitment to life issues,” Cassidy said. “The Administration withdrew Dr. Overton rather than make such commitments.” Sen. Roger Marshall, R-Kansas, is being weighed as a potential replacement, but there are questions swirling about whether anyone could be confirmed on a compressed timeline before Democrats take power.

Chris Meekins, a Raymond James healthcare analyst who worked at HHS during Trump’s first term, predicted the FDA will not have a permanent leader anytime soon, a development that “inevitably creates uncertainty.” “Had the White House heeded warnings by many before and after her nomination, they could have avoided this unfortunate outcome,” Meekins said.

Related stories